



Please type a plus sign (+) inside this box


+

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known	
		Application Number	09/816,839
(Use as many sheets as necessary)		Filing Date	MARCH 23, 2001
		First Named Inventor	Michael FUNG, et al.
		Group Art Unit	1645 1644
		Examiner Name	VanderKest NOT YET ASSIGNED
		Attorney Docket Number	TNX 00-04
SHEET	1	OF	4

U.S. PATENT DOCUMENTS					
Examiner Initials	U.S. Documents		U.S. Patent Document Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Number	Kind Code (if known)			
RV	5,225,539	B1	G. WINTER	July 6, 1993	
	5,530,101	B1	C. QUEEN, et al.	June 25, 1996	
	4,946,778	B1	LADNER, et al.	AUG. 7, 1990	

FOREIGN DOCUMENTS							
Examiner Initials	Foreign Patent Documents			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
	Office	Number	Kind Code (if known)				

Examiner Signature		Date Considered	2/21/05
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Applicati n Numb r	09/816,839
Filing Dat	MARCH 23, 2001
First Named Inv ntor	Michael FUNG, et al.
Group Art Unit	1045 1644
Examiner Name	VANDERVEET NOT YET ASSIGNED
Attorney Docket Number	TXN 00-04


Use as many sheets as necessary)

SHEET

2

OF

4



OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, volume-issue number(s), page(s).	T 2
A	1.	M. MATSUSHITA, "The Lectin Pathway of the Complement System", <i>Microbiol. Immunol.</i> 40(12):887-893 (1996).	
	2	M. MATSUSHITA, et al., "MASP-1 (MBL-Associated Serine Protease-1)", <i>Immunobiol.</i> 199:340-347 (1998).	
	3	C. SUANKRATAY, et al., "Requirement for the Alternative Pathway as well as C4 and C2 in Complement-Dependent Hemolysis via the Lectin Pathway", <i>J. Immunol.</i> 160:3006-3013 (1998).	
	4	Y. ZHANG, et al., "Lysis via the Lectin Pathway of Complement Activation: minireview and lectin pathway enhancement of endotoxin-initiated hemolysis", <i>Immunopharmacol.</i> 42:81-90 (1999).	
	5	Y. ZHANG, et al., "Calcium-Independent Haemolysis via the Lectin Pathway of Complement Activation in the Guinea-Pig and Other Species", <i>Immunol.</i> 97:686-692 (1999).	
	6	HANS-PETER HEINZ, et al., "Monoclonal Antibodies Against Components of the Classical Pathway of Complement", <i>Complement Inflamm.</i> 6:166-174 (1989).	
	7	V.M. HOLERS, "Complement", IN: <u>CLINICAL IMMUNOLOGY: PRINCIPLES AND PRACTICE</u> , R.R. RICH Ed., MOSBY PRESS, 1996, pp. 363-391.	
	8	VORUP-JENSEN, et al., "MASP-2, the C3 Convertase Generating Protease of the MBlectin Complement Activating Pathway", <i>Immunobiol.</i> 199: 348-357 (1998).	
	9	C. SUANKRATAY, et al., "Complement Regulation in Innate Immunity and the Acute-Phase Response: Inhibition of Mannan-Binding Lectin-Initiated Complement Cytolysis of C-Reactive Protein", <i>Clin. Exp. Immunol.</i> 113:353-359 (1998).	
	10	C. SUANKRATAY, et al., "Mechanism of Complement-Dependent Haemolysis via the Lectin Pathway: Role of the Complement Regulatory Proteins", <i>Clin. Exp. Immunol.</i> 117: 442-448 (1999).	
	11	R. SCHLINDER, et al., "Recombinant C5a Stimulates Transcription Rather Than Translation of Interleukin-1 (IL-1) and Tumor Necrosis Factor: Translational Signal Provided by Lipopolysaccharide or IL-1 Itself", <i>Blood</i> 76:1631-1638 (1990).	
	12	T. WIEDMER et al., "Participation of Protein Kinases in Complement C5b-9-Induced Shedding of Platelet Plasma Membrane Vesicles", <i>Blood</i> 78:2880-2886 (1991).	
	13	M. P. FLETCHER, et al., "C5a-Induced Myocardial Ischemia: Role for CD18-Dependent PMN Localization and PMN-Platelet Interactions", <i>Am. J. Physiol.</i> 265:h1750-1761 (1993).	
	14	S. NAGASAWA, et al., "Cleavage of C2 by C1s into Antigenically Distinct Fragments C2a and C2b: Demonstration of Binding of C2b to C4b", <i>Proc. Natl. Acad. Sci. (USA)</i> 74:2998-3001 (1977).	
Examiner Signature		Date Considered 2/21/05	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

3

OF

4

Complete if Known

Applicati n Numb r	09/816,839
Filing Dat	MARCH 23, 2001
First Named Inv nt r	Michael FUNG, et al.
Gr up Art Unit	1845-1644
Examln r Nam	Under Vgt NOT YET ASSIGNED
Attorney Docket Number	TNX 00-04

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²
<i>pr</i>	15	E. I. STENBAEK, et al., "Human Complement Component C2: Production and Characterization of Polyclonal and Monoclonal Antibodies Against C2", <i>Mol. Immunol.</i> 23:879-886 (1986).	7
	16	T. J. OGLESBY, et al., "Evidence for a C4b Binding Site on the C2b Domain of C2", <i>J. Immunol.</i> 141:926-931 (1988).	9
	17	Y. WANG, et al., "Amelioration of Lupus-Like Autoimmune Disease in NZB/W F ₁ Mice After Treatment With a Blocking Monoclonal Antibody Specific for Complement Component C5", <i>Proc. Natl. Acad. Sci. (USA)</i> , 1996, 93:8563-8568	
	18	C. S. RINDER, et al., "Blockade of C5a and C5b Generation Inhibits Leukocyte and Platelet Activation During Extracorporeal Circulation", <i>J Clin. Invest.</i> 96:1564-1572 (1995).	
	19	J. C. K. FITCH, et al., "Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass", <i>Circulation</i> 100:2499-2506 (1999).	
	20	H. L. LAZAR, et al., "Total Complement Inhibition: An Effective Strategy to Limit Ischemic Injury During Coronary Revascularization on Cardiopulmonary Bypass", <i>Circulation</i> 100:1438-1442 (1999).	
	21	T. J. KROSHUS, et al., "Complement Inhibition with an Anti-C5 Monoclonal Antibody Prevents Acute Cardiac Tissue Injury in an Ex Vivo Model of Pig-To-Human Xenotransplantation", <i>Transplantation</i> 60:1194-1202 (1995).	
	22	J. W. HOMEISTER, et al., "Soluble Complement Receptor Type 1 Prevents Human Complement-Mediated Damage of the Rabbit Isolated Heart", <i>J. Immunol.</i> 150: 1055-1064 (1993).	
	23	H. F. WEISMAN, et al., "Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis", <i>Science</i> 249:146-151 (1990).	
	24	E. A. AMSTERDAM, et al., "Limitation of Reperfusion Injury by a Monoclonal Antibody to C5a during Myocardial Infarction in Pigs", <i>Am. J. Physiol.</i> 268: H448-H457 (1995).	
	25	R. RABINOVICI, et al., "Role of Complement in Endotoxin/Platelet-Activating Factor-Induced Lung Injury", <i>J. Immunol.</i> 149:1744-1750 (1992).	
	26	B. P. MORGAN, "Clinical Complementology: Recent Progress and Future Trends", <i>Eur. J. Clin. Invest.</i> 24:219-228 (1994).	
	27	S. M. CANFIELD, et al., "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the C _H 2 Domain and is Modulated by the Hinge Region", <i>J. Exp. Med.</i> 173:1483-1491 (1991).	
Examiner Signature	<i>[Signature]</i>		Date Considered 2/21/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

SHEET

4



OF

4

Complete if Known

Application Number	09/816,839
Filing Date	MARCH 23, 2001
First Named Inventor	Michael FUNG, et al.
Group Art Unit	1645 1644
Examiner Name	VanderVest NOT YET ASSIGNED
Attorney Docket Number	TNX 00-04

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).	T ²
	28	KOHLER AND MILSTEIN, "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity", <i>Nature</i> 256: 495-497 (1975).	
	29	Y. XU, et al., "Residue at Position 331 in the IgG1 and IgG4 C _H 2 Domains Contributes to Their Differential Ability to Bind and Activate Complement", <i>J. Biol. Chem.</i> 269:3469-3474 (1994).	
	30	V. L. PULITO, et al., "Humanization and Molecular Modeling of the Anti-CD4 Monoclonal Antibody, OKT4A", <i>J. Immunol.</i> 156:2840-2850 (1996).	
	31	L. RIECHMANN, et al., "Reshaping Human Antibodies for Therapy", <i>Nature</i> 332:323-327 (1988).	
	32	M. J. EVANS, et al., "Rapid Expression of an Anti-Human C5 Chimeric Fab Utilizing a Vector That Replicates in COS and 293 Cells", <i>J. Immunol. Meth.</i> 184:123-138 (1995).	
	33	S.K. DATTA, "Murine Lupus", <i>Meth. Enzymol.</i> 162:385-413 (1988).	
	34	D. J. SALVANT, et al., "Experimental Glomerulonephritis", <i>Meth. Enzymol.</i> 162:421-461 (1988).	
	35	Y. WANG, et al., "Anti C5 Monoclonal Antibody Therapy Prevents Collagen-Induced Arthritis and Ameliorates Established Disease", <i>Proc. Natl. Acad. Science (USA)</i> 92:8955-8959 (1995).	
	36	M. S. MULLIGAN, et al., "Protective Effects of Soluble CR1 in Complement- and Neutrophil-Mediated Tissue Injury", <i>J. Immunol.</i> 148:1479-1485 (1992).	
Examiner Signature			Date Considered 2/21/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.